The new blood test will help determine the necessary treatments and medicines to reduce the chances of hospitalisation.
The company stated that the test has been validated by a longitudinal study, which was conducted in collaboration with physicians in the Pulmonary and Critical Care Medicine division of the University of Virginia (UVA) Medical Center in the US.
CovGENE showed remarkable precision, with an accuracy of more than 90%, when analysing patients admitted to the UVA Intensive Care Unit.
The test is administered by simply drawing blood from a Covid-19 patient and quickly determines whether the patient will have a mild, moderate or severe outcome.
AMPEL chief medical officer, CEO and co-founder Dr Peter Lipsky said: “This unique collaboration with our colleagues from the University of Virginia has provided an easy and novel means to assess an individual patient’s response to the SARS-CoV-2 virus and predict the clinical outcome.
“Now that this unique approach has been validated, we look forward to its rapid development as a precision medicine tool that can improve the outcome of patients with Covid-19 and reduce the number of hospitalisations, especially the most vulnerable.”
At present, the company is working to collaborate with a diagnostic testing company to make CovGENE available to the public.
Additionally, AMPEL claims that the blood test can predict long COVID, an elusive diagnosis that the medical community is still trying to completely understand.
Through this simple blood test, the company’s new approach is expected to expedite the means of providing effective treatments.